Amanda R. Strohm
Research Subjects
Amanda R. Strohm has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
M.R.K. Alley
AN2 Therapeutics
2 shared publications- Peter J. Tonge
Stony Brook University
2 shared publications - Gauri Shetye
Department of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago
1 shared publication - John D. Haley
Stony Brook University School of Medicine
1 shared publication Mingqian Wang
Center for Advanced Study of Drug Action, and Department of Chemistry
1 shared publication- Mingqian Wang
Center for Advanced Study of Drug Action, and Department of Chemistry
1 shared publication
Latest Publications
- 3 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (12) , 2955-2965
Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability
Ganfeborole (GSK3036656) inhibits the Mycobacterium tuberculosis leucyl-tRNA-synthetase (mtLeuRS) and is in Phase 2a clinical trials for the treatment of tuberculosis. Here we show that ganfeborole is a time-dependent inhibitor of mtLeuRS (IC50 1 nM) and generates a postantibiotic effect of 77 h at 50xMIC (MIC 0.058 μM) with M. tuberculosis H37Rv, indicating that mtLeuRS is a highly vulnerable drug target and supporting the excellent in vivo efficacy of the drug. Ganfeborole is also a potent time-dependent inhibitor of Escherichia coli LeuRS (ecLeuRS, IC50 2 nM), however no antibacterial activity is observed toward E. coli up to 1 mM ganfeborole despite the observation that less potent ganfeborole analogs have antibacterial activity. To rationalize this observation, we propose that ganfeborole forms a complex with AMP that binds to the ecLeuRS editing site but does not impact aminoacylation. In support, addition of 12.5 μM norvaline generates a ganfeborole MIC of 0.4 μM since ecLeuRS is unable to hydrolyze norvaline-tRNALeu. Additionally, mutations that reduce the affinity and residence time of ganfeborole-AMP on ecLeuRS result in antibacterial activity. We propose that the activity of ganfeborole toward M. tuberculosis is because mtLeuRS is a highly vulnerable target so that only low levels of enzyme need to be inhibited by the ganfeborole-tRNALeu complex in contrast to ecLeuRS, which we previously demonstrated is a low vulnerability target.
- 3 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 20 (12) , 2955-2965
Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability
Ganfeborole (GSK3036656) inhibits the Mycobacterium tuberculosis leucyl-tRNA-synthetase (mtLeuRS) and is in Phase 2a clinical trials for the treatment of tuberculosis. Here we show that ganfeborole is a time-dependent inhibitor of mtLeuRS (IC50 1 nM) and generates a postantibiotic effect of 77 h at 50xMIC (MIC 0.058 μM) with M. tuberculosis H37Rv, indicating that mtLeuRS is a highly vulnerable drug target and supporting the excellent in vivo efficacy of the drug. Ganfeborole is also a potent time-dependent inhibitor of Escherichia coli LeuRS (ecLeuRS, IC50 2 nM), however no antibacterial activity is observed toward E. coli up to 1 mM ganfeborole despite the observation that less potent ganfeborole analogs have antibacterial activity. To rationalize this observation, we propose that ganfeborole forms a complex with AMP that binds to the ecLeuRS editing site but does not impact aminoacylation. In support, addition of 12.5 μM norvaline generates a ganfeborole MIC of 0.4 μM since ecLeuRS is unable to hydrolyze norvaline-tRNALeu. Additionally, mutations that reduce the affinity and residence time of ganfeborole-AMP on ecLeuRS result in antibacterial activity. We propose that the activity of ganfeborole toward M. tuberculosis is because mtLeuRS is a highly vulnerable target so that only low levels of enzyme need to be inhibited by the ganfeborole-tRNALeu complex in contrast to ecLeuRS, which we previously demonstrated is a low vulnerability target.
- 2 April 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (4) , 977-985
Time-Dependent Inhibition of Leucyl-tRNA-Synthetase (LeuRS): Insight into Target Vulnerability
The postantibiotic effect (PAE) is the persistent suppression of microbial growth following the removal of antimicrobial therapy. In general, antibiotics that generate a PAE are dosed less frequently, and thus, the PAE has important implications for dosing regimens. PAEs can arise through several mechanisms, including the extended occupancy of the drug target following drug elimination, and the correlation between drug-target residence time and PAE provides insight into target vulnerability. To assess the vulnerability of Escherichia coli leucyl-tRNA synthetase (ecLeuRS), which is an essential enzyme in protein synthesis, the time-dependent inhibition of the enzyme was studied by the benzoxaborole class of compounds that inhibit LeuRS by forming a stable LeuRS-tRNALeu-benzoxaborole adduct. Preincubation of epetraborole with ecLeuRS resulted in a decrease in the IC50 value for enzyme inhibition from 38 to 3 nM, consistent with the slow formation of the final enzyme-inhibitor complex, and similar shifts in IC50 were observed for three other benzoxaboroles. The benzoxaboroles generated short PAEs (E. coli, however, the PAE values of AN3334 and epetraborole increased from 0.88 to 1.70-3 h when a sub-MIC concentration of the aminoglycoside tobramycin was included in the media. pSILAC revealed that the synthesis rate of ecLeuRS was reduced 1.6-fold in the presence of sub-MIC tobramycin, reinforcing the role that protein turnover plays in target vulnerability.
- 2 April 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (4) , 977-985
Time-Dependent Inhibition of Leucyl-tRNA-Synthetase (LeuRS): Insight into Target Vulnerability
The postantibiotic effect (PAE) is the persistent suppression of microbial growth following the removal of antimicrobial therapy. In general, antibiotics that generate a PAE are dosed less frequently, and thus, the PAE has important implications for dosing regimens. PAEs can arise through several mechanisms, including the extended occupancy of the drug target following drug elimination, and the correlation between drug-target residence time and PAE provides insight into target vulnerability. To assess the vulnerability of Escherichia coli leucyl-tRNA synthetase (ecLeuRS), which is an essential enzyme in protein synthesis, the time-dependent inhibition of the enzyme was studied by the benzoxaborole class of compounds that inhibit LeuRS by forming a stable LeuRS-tRNALeu-benzoxaborole adduct. Preincubation of epetraborole with ecLeuRS resulted in a decrease in the IC50 value for enzyme inhibition from 38 to 3 nM, consistent with the slow formation of the final enzyme-inhibitor complex, and similar shifts in IC50 were observed for three other benzoxaboroles. The benzoxaboroles generated short PAEs (E. coli, however, the PAE values of AN3334 and epetraborole increased from 0.88 to 1.70-3 h when a sub-MIC concentration of the aminoglycoside tobramycin was included in the media. pSILAC revealed that the synthesis rate of ecLeuRS was reduced 1.6-fold in the presence of sub-MIC tobramycin, reinforcing the role that protein turnover plays in target vulnerability.